137 related articles for article (PubMed ID: 31927399)
1. Expression of Lewis (b) blood group antigen interferes with oral dienogest therapy among women with adenomyosis.
Xue J; Li L; Li F; Li N; Li T; Li C
J Reprod Immunol; 2020 Feb; 137():103079. PubMed ID: 31927399
[TBL] [Abstract][Full Text] [Related]
2. Long-term dienogest administration in patients with symptomatic adenomyosis.
Neriishi K; Hirata T; Fukuda S; Izumi G; Nakazawa A; Yamamoto N; Harada M; Hirota Y; Koga K; Wada-Hiraike O; Fujii T; Osuga Y
J Obstet Gynaecol Res; 2018 Aug; 44(8):1439-1444. PubMed ID: 29845696
[TBL] [Abstract][Full Text] [Related]
3. Comparison of dienogest versus combined oral contraceptive pills in the treatment of women with adenomyosis: A randomized clinical trial.
Hassanin AI; Youssef AA; Yousef AM; Ali MK
Int J Gynaecol Obstet; 2021 Aug; 154(2):263-269. PubMed ID: 33454995
[TBL] [Abstract][Full Text] [Related]
4. Combination of microwave endometrial ablation and postoperative dienogest administration is effective for treating symptomatic adenomyosis.
Ota K; Takahashi T; Shiraishi S; Mizunuma H
J Obstet Gynaecol Res; 2018 Sep; 44(9):1787-1792. PubMed ID: 29998482
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of dienogest in the treatment of symptomatic adenomyosis: a pilot study.
Hirata T; Izumi G; Takamura M; Saito A; Nakazawa A; Harada M; Hirota Y; Koga K; Fujii T; Osuga Y
Gynecol Endocrinol; 2014 Oct; 30(10):726-9. PubMed ID: 24905725
[TBL] [Abstract][Full Text] [Related]
6. Comparison of dienogest versus triptorelin acetate in premenopausal women with adenomyosis: a prospective clinical trial.
Fawzy M; Mesbah Y
Arch Gynecol Obstet; 2015 Dec; 292(6):1267-71. PubMed ID: 25990480
[TBL] [Abstract][Full Text] [Related]
7. Long-term use of dienogest in the treatment of painful symptoms in adenomyosis.
Osuga Y; Watanabe M; Hagino A
J Obstet Gynaecol Res; 2017 Sep; 43(9):1441-1448. PubMed ID: 28737239
[TBL] [Abstract][Full Text] [Related]
8. Dienogest reduces proliferation, NGF expression and nerve fiber density in human adenomyosis.
Takeuchi A; Koga K; Miyashita M; Makabe T; Sue F; Harada M; Hirata T; Hirota Y; Fujii T; Osuga Y
Eur J Obstet Gynecol Reprod Biol; 2016 Dec; 207():157-161. PubMed ID: 27865118
[TBL] [Abstract][Full Text] [Related]
9. Recurrence of uterine adenomyosis after administration of gonadotropin-releasing hormone agonist and the efficacy of dienogest.
Matsushima T; Akira S; Yoneyama K; Takeshita T
Gynecol Endocrinol; 2020 Jun; 36(6):521-524. PubMed ID: 31661345
[TBL] [Abstract][Full Text] [Related]
10. Long-term treatment of dienogest with symptomatic adenomyosis: retrospective analysis of efficacy and safety in clinical practice.
Miao J; Lu J; Tang J; Lu P
Gynecol Endocrinol; 2022 Aug; 38(8):656-660. PubMed ID: 35850637
[No Abstract] [Full Text] [Related]
11. Evaluating the safety of dienogest in women with adenomyosis: A retrospective analysis.
Ono N; Asano R; Nagai K; Sugo Y; Nakamura T; Miyagi E
J Obstet Gynaecol Res; 2021 Apr; 47(4):1433-1440. PubMed ID: 33590656
[TBL] [Abstract][Full Text] [Related]
12. A cohort study of the efficacy of the dienogest and the gonadotropin-releasing hormone agonist in women with adenomyosis and dysmenorrhea.
Ji M; Yuan M; Jiao X; Li Q; Huang Y; Li J; Wang G
Gynecol Endocrinol; 2022 Feb; 38(2):164-169. PubMed ID: 34749585
[TBL] [Abstract][Full Text] [Related]
13. Current and Future Medical Therapies for Adenomyosis.
Cope AG; Ainsworth AJ; Stewart EA
Semin Reprod Med; 2020 May; 38(2-03):151-156. PubMed ID: 33124017
[TBL] [Abstract][Full Text] [Related]
14. Effective salvage of acute massive uterine bleeding using intrauterine balloon tamponade in a uterine adenomyosis patient on dienogest.
Nishino K; Hayashi K; Chaya J; Kato N; Yamamuro O
J Obstet Gynaecol Res; 2013 Mar; 39(3):738-41. PubMed ID: 23003209
[TBL] [Abstract][Full Text] [Related]
15. Subtype I (intrinsic) adenomyosis is an independent risk factor for dienogest-related serious unpredictable bleeding in patients with symptomatic adenomyosis.
Matsubara S; Kawaguchi R; Akinishi M; Nagayasu M; Iwai K; Niiro E; Yamada Y; Tanase Y; Kobayashi H
Sci Rep; 2019 Nov; 9(1):17654. PubMed ID: 31776404
[TBL] [Abstract][Full Text] [Related]
16. Relief of uterine bleeding by cyclic administration of dienogest for endometriosis.
Yanase T; Tsuneki I; Tamura M; Kurabayashi T
Gynecol Endocrinol; 2014 Nov; 30(11):804-7. PubMed ID: 25060125
[TBL] [Abstract][Full Text] [Related]
17. A dose-ranging study to determine the efficacy and safety of 1, 2, and 4mg of dienogest daily for endometriosis.
Köhler G; Faustmann TA; Gerlinger C; Seitz C; Mueck AO
Int J Gynaecol Obstet; 2010 Jan; 108(1):21-5. PubMed ID: 19819448
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study.
Osuga Y; Fujimoto-Okabe H; Hagino A
Fertil Steril; 2017 Oct; 108(4):673-678. PubMed ID: 28911934
[TBL] [Abstract][Full Text] [Related]
19. Long-term use of dienogest for the treatment of primary and secondary dysmenorrhea.
Osuga Y; Hayashi K; Kanda S
J Obstet Gynaecol Res; 2020 Apr; 46(4):606-617. PubMed ID: 32050307
[TBL] [Abstract][Full Text] [Related]
20. Risk factors of treatment discontinuation due to uterine bleeding in adenomyosis patients treated with dienogest.
Nagata C; Yanagida S; Okamoto A; Morikawa A; Sugimoto K; Okamoto S; Ochiai K; Tanaka T
J Obstet Gynaecol Res; 2012 Apr; 38(4):639-44. PubMed ID: 22413833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
